Stay updated on Ipilimumab Nivolumab in Small Cell Lung Cancer Clinical Trial
Sign up to get notified when there's something new on the Ipilimumab Nivolumab in Small Cell Lung Cancer Clinical Trial page.

Latest updates to the Ipilimumab Nivolumab in Small Cell Lung Cancer Clinical Trial page
- CheckyesterdayChange DetectedThe ClinicalTrials.gov record for a Yale University study of ipilimumab and nivolumab in recurrent extensive-stage small cell lung cancer is now displayed, including its study design, participant criteria, and outcome measures. The study is listed as active but not recruiting.SummaryDifference46%

- Check8 days agoChange DetectedThe footer revision changed from v3.7.2 to v3.8.0. The page still displays a 403 Forbidden error instead of study information.SummaryDifference0.2%

- Check14 days agoChange DetectedA banner announces that NIH is transitioning terminology from “Artificial Intelligence” to “Super Intelligence.” The study record area continues to display a 403 error.SummaryDifference1%

- Check21 days agoChange DetectedThe site footer revision changes from v3.7.1 to v3.7.2, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check28 days agoChange DetectedThe footer now identifies the site revision as v3.7.1 instead of v3.7.0.SummaryDifference0.2%

- Check42 days agoChange DetectedThe page now displays a 403 Forbidden error with standard HTML boilerplate and a Home link, replacing the study record view.SummaryDifference0.5%

Stay in the know with updates to Ipilimumab Nivolumab in Small Cell Lung Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Ipilimumab Nivolumab in Small Cell Lung Cancer Clinical Trial page.